Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEXO.L Regulatory News (EXO)

  • There is currently no data for EXO

Trading Statement

11 Nov 2015 07:00

RNS Number : 2597F
Exova Group PLC
11 November 2015
Β 

11 November 2015

Exova Group plc

Trading Update

Organic growth on track and acquisitions performing to planΒ 

Exova Group plc ("Exova"), a leading international provider of technically demanding testing, certification and advisory services, today releases a Trading Update for the period since 30 June 2015 to date. Where stated, financial results are for the period from 1 January to 31 October 2015 compared with the corresponding period in 2014.

Group performance for the ten months to 31 October 2015

Β 

Β· Revenue up 9.3% at constant currency; 7.5% at actual rates

o 2.7% organic growth at constant currency (7.6% excluding Oil & Gas and Industrials)

o 6.6% growth from M&A activity

Β· BM TRADA acquisition integrating well and performing in line with expectations

Β· M&A pipeline continues to be strong

Β· Outlook for 2015 earnings remains unchanged

Regional performance in the period from 1 July 2015 to date

Β 

In Europe, we saw good organic growth in our Health Sciences and Product & Certification clusters. The integration of BM TRADA, which we acquired in May this year, has gone well and the business is on track to deliver in line with expectations for 2015 and to realise the planned synergies in 2016. As expected, the impact of low oil prices has led to further contraction and price pressure in our Oil & Gas and Industrials cluster.

Organic revenues in the Americas have improved as we continued to see good progress in the Aerospace and Transportation sectors. Our Oil & Gas and Industrials cluster has experienced similar headwinds to Europe.

Β 

In Rest of World, strong growth has continued in the Middle East and the pipeline of new contracts looks strong into 2016.

We have continued to take restructuring actions across the Group to mitigate the impact on margin where we face market headwinds.

Outlook

Β 

The Board confirms previous guidance for full year earnings in 2015. Restructuring costs will also be in line with expectations.

Β 

Ian El-Mokadem, Chief Executive Officer, commented:

Β 

"I am pleased with our overall performance for the year to date. We have seen good growth in most of our sectors and are making very good progress with acquisitions."

Β 

Full year results

The Group's full year results to 31 December 2015 will be announced on 2 March 2016.

Β 

Contacts

Β 

Ian Middleton / Sophie Moate

Powerscourt Group

Tel. Direct +44 (0)20 7250 1446 / +44 (0)7885 508 527

exova@powerscourt-group.com

Β 

Ian Power, Investor Relations

Exova Group plc

Telephone: +44 (0) 131 476 7619

investor.relations@exova.com

Β 

Β 

About Exova

Exova is one of the world's leading laboratory-based testing groups, trusted by organisations to test and advise on the safety, quality and performance of their products and operations. Headquartered in Edinburgh, UK Exova operates 143Β laboratories and offices in 32 countries and employs around 4,500 people throughout Europe, the Americas, the Middle East and Asia/Asia Pacific.

Exova's capabilities help to extend asset life, bring predictability to applications, and shorten the time to market for customers' products, processes and materials. With over 90 years' experience, Exova specialises in testing across a number of key sectors from health sciences to aerospace, transportation, oil and gas, fire and construction.

This Trading Update release contains forward-looking statements that involve substantial risks and uncertainties and actual results and developments may differ materially from those expressed or implied by these statements by a variety of factors. These forward-looking statements speak only as at the date of this press release. In addition, all projections, valuations and statistical analyses provided in this document may be based on unaudited pro-forma financial information, subjective assessments and assumptions. They may use alternative methodologies that produce different results and should not be relied upon as an accurate prediction of future performance.

Β 

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTPKKDNOBDDQDD
Date   Source Headline
24th May 20173:11 pmRNSDirector/PDMR Shareholding
24th May 20171:40 pmRNSResult of AGM
24th May 20171:32 pmRNSAGM Statement
24th May 201712:34 pmRNSForm 8.5 (EPT/RI) - Amendment
24th May 201712:02 pmRNSForm 8.5 (EPT/NON-RI) - Exova Group Plc
24th May 201712:00 pmRNSForm 8.5 (EPT/RI) - Exova Group Plc
24th May 201711:08 amRNSForm 8.3 - Exova Group PLC
24th May 201710:57 amRNSDirector Declaration
24th May 201710:32 amRNSForm 8.5 (EPT/RI)
24th May 201710:13 amRNSForm 8.5 (EPT/RI)
24th May 20179:45 amRNSForm 8.3 - EXOVA GROUP PLC
24th May 20177:00 amRNSTrading Statement
23rd May 201712:20 pmRNSForm 8.5 (EPT/RI) - Exova Group Plc
23rd May 201711:57 amRNSForm 8.3 - Exova Group Plc
23rd May 201710:35 amRNSForm 8.5 (EPT/RI)
22nd May 20173:30 pmRNSForm 8.3 - EXO LN
22nd May 20173:18 pmRNSForm 8.3 - Exova Group Plc
22nd May 201711:52 amRNSForm 8.5 (EPT/RI) - Exova Group Plc
22nd May 201710:34 amRNSForm 8.5 (EPT/RI)
19th May 20172:53 pmBUSForm 8.3 - Exova Group Plc
19th May 20172:03 pmRNSForm 8.3 - [Exova Group Plc]
19th May 20171:57 pmRNSForm 8.3 - Exova Group Plc
19th May 20171:11 pmRNSForm 8.5 (EPT/RI)
19th May 20171:03 pmRNSForm 8.3 - EXOVA GROUP PLC
19th May 201711:35 amRNSForm 8.5 (EPT/RI) Exova Group Plc
19th May 201711:26 amRNSForm 8.5 (EPT/RI)
18th May 201712:22 pmRNSForm 8.3 - Exova Group Plc
18th May 201711:53 amRNSForm 8.5 (EPT/RI) - Exova Group Plc
18th May 201711:52 amRNSForm 8.5 (EPT/NON-RI) - Exova Group Plc
18th May 201711:19 amRNSForm 8.5 (EPT/RI)
18th May 201711:12 amRNSForm 8.3 - Exova Group PLC
18th May 201710:50 amRNSForm 8.5 (EPT/RI)
18th May 20178:30 amRNSAcquisition
17th May 20174:52 pmRNSForm 8.5 (EPT/RI) - Amendment
17th May 20172:56 pmRNSForm 8.3 - Exova Group Plc
17th May 20172:25 pmBUSForm 8.3 - Exova Group Plc
16th May 20172:54 pmBUSForm 8.3 - Exova Group Plc
16th May 201711:52 amRNSForm 8.5 (EPT/RI)
16th May 201711:49 amRNSForm 8.5 (EPT/RI) - Exova Group Plc
16th May 201710:26 amRNSForm 8.3 - EXOVA GROUP PLC
16th May 201710:25 amRNSForm 8.5 (EPT/RI)
15th May 20173:30 pmRNSForm 8.3 - EXO LN
15th May 201711:54 amRNSForm 8.5 (EPT/RI) - Exova Group Plc
15th May 201711:44 amRNSForm 8.3 - Exova Group PLC
15th May 201711:13 amRNSForm 8.5 (EPT/RI)
15th May 201710:41 amRNSForm 8.5 (EPT/RI)
15th May 20179:44 amRNSForm 8.3 - EXOVA GROUP PLC
15th May 20179:39 amRNSDeadline for clarification by Jacobs and PAI
12th May 20173:43 pmRNSRECOMMENDED ACQUISITION OF EXOVA REGULATORY UPDATE
12th May 201711:29 amRNSForm 8.5 (EPT/RI) - Exova Group Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.